Kejun Nan

机构：First Affiliated Hospital of Xi'an Jiaotong University · ORCID：0000-0002-9068-7488

发表论文 62 篇 · 总被引 4325 次 · h-index 20

代表论文

• Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial (2019 · The Lancet · 被引 2271)
• Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial (2020 · The Lancet Oncology · 被引 704)
• Management of anlotinib‐related adverse events in patients with advanced non‐small cell lung cancer: Experiences in ALTER‐0303 (2019 · Thoracic Cancer · 被引 74)
• The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update (2024 · 癌症：英文版 · 被引 70)
• CNV Detection from Circulating Tumor DNA in Late Stage Non-Small Cell Lung Cancer Patients (2019 · Genes · 被引 52)
• NK cell‑produced IFN‑γ regulates cell growth and apoptosis of colorectal cancer by regulating IL‑15 (2019 · Experimental and Therapeutic Medicine · 被引 41)